Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Bill Kelly

BioCT welcomes new member Greenfield BioVentures

Greenfield BioVentures is an investment company focused on early-stage science in the biopharmaceuticals space. Its preferred investments are typically in pre-clinical stages of experimentation and in...

| By Bill Kelly

GestVision reports on urine test for preeclampsia

GestVision reports researchers have demonstrated that CRD (Congo Red Dot) urine diagnostic test results strongly correlate with a diagnosis of preeclampsia. “This is an important...

| By Bill Kelly

Biohaven acquires Priority Review Voucher

Biohaven Pharmaceutical Holding Company has purchased an FDA Priority Review Voucher to use with the NDA submission of rimegepant Zydis® ODT in the second quarter of 2019 …...

| By Kelley Gipson

Cybrexa unveils rucaparib as PARP inhibitor

Cybrexa Therapeutics reports that the FDA- and EMA-approved poly ADP-ribose polymerase (PARP) inhibitor rucaparib (marketed as Rubraca®) is conjugated in lead candidate CBX-11 (alphalex™-rucaparib). The...

| By Kelley Gipson

Farmington’s CaroGen lands $1.4M grant re HBV

Farmington-based immunotherapy startup CaroGen reports it has won a $1.4 million grant from the National Institutes of Health to accelerate development of its lead drug candidate, a potential...

| By Kelley Gipson

5/1 deadline for ‘Innovation to Impact’ grants

Innovation to Impact at Yale announces a small grant competition for promising innovators committed to addressing substance abuse and addiction. Innovators will apply for one...

| By Kelley Gipson

Cybrexa to present data re its lead candidate

Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the upcoming...